Search results
-
ASH 2023 – Genmab's son of Darzalex in focus
ASH 2023 – Genmab's son of Darzalex in focus … development of GEN3014 . GEN3014 safety data at ASH 2023 Source: Dr Sebastian Grosicki & ASH. …
- 12/15/2023 - 13:39 -
ASH 2023 – Arcellx still hopes to challenge Carvykti
ASH 2023 – Arcellx still hopes to challenge Carvykti …
- 12/14/2023 - 17:01 -
ASH 2023 – the markets forgive MorphoSys
ASH 2023 – the markets forgive MorphoSys …
- 04/26/2024 - 15:06 -
ASH 2023 – Regeneron defends its bispecifics
ASH 2023 – Regeneron defends its bispecifics …
- 12/12/2023 - 05:08 -
ASH 2023 – a short-lived success for Poseida
ASH 2023 – a short-lived success for Poseida …
- 12/12/2023 - 01:08 -
ASH 2023 – Incyte hopes to add axatilimab to the arsenal
ASH 2023 – Incyte hopes to add axatilimab to the arsenal … Axatilimab Anti-CSF-1R Mab Syndax/ Incyte ASH 2023: 74% ORR at lowest dose in ≥3L chronic GvHD in …
- 12/12/2023 - 01:09 -
ASH 2023 – lacutamab’s late-line promise on hold
ASH 2023 – lacutamab’s late-line promise on hold …
- 12/10/2023 - 22:45 -
ASH 2023 – sense and serendipity in Dizal's Jackpot win
ASH 2023 – sense and serendipity in Dizal's Jackpot win …
- 12/11/2023 - 22:05 -
ASH 2023 – a new EZ battle shapes up
ASH 2023 – a new EZ battle shapes up … Cross-trial comparison of EZH1/2 inhibitors at ASH 2023 Company Daiichi Sankyo Haihe … TRAE leading to death 0% 3% Source: ASH 2023. On the face of it HH2853 looks slightly …
- 01/10/2024 - 18:06 -
ASH 2023 – lupus target could work in lymphoma too
ASH 2023 – lupus target could work in lymphoma too …
- 12/10/2023 - 22:44
